You're not looking for a wellness blog post. You're looking for something you can actually act on — a referral pathway that has clinical credibility, a program grounded in real research, and an answer you can give patients who have been cycling through sleep medications for years without getting better. This is that post.
Let's start with what the evidence says, work through why medication keeps getting prescribed anyway, and land on what you can realistically offer instead.
Every clinician who prescribes sleep medication for an older patient already knows the issues, at least abstractly. The Beers Criteria exists for a reason. Z-drugs and benzodiazepines carry explicit fall and fracture warnings in adults over 65. The residual sedation from zolpidem, temazepam, or eszopiclone in an aging liver can extend well past morning, impairing balance and reaction time during hours when the patient feels functionally awake. The side effects of Ambien that patients and clinicians should know include next-day psychomotor impairment that is dose-dependent and worse in older adults — not theoretical, but documented in driving simulation studies.
The newer dual orexin receptor antagonists — suvorexant (Belsomra), lemborexant (Dayvigo), quviviq (daridorexant) — are sometimes positioned as safer alternatives, but they carry their own profiles worth understanding carefully. The dangers of Belsomra and its side effects, Dayvigo's potential risks, and the dark side of Quviviq all point to next-day somnolence and residual impairment risks that remain meaningful in older, frailer patients — despite improved receptor selectivity.
Trazodone is often the default "safer" off-label choice, but the evidence for its efficacy in primary insomnia is weak, and its half-life creates orthostatic hypotension risk that is directly relevant to fall outcomes in older adults. How long trazodone lasts in the system is something many prescribers don't fully account for when dosing. Trazodone versus Ambien and how they compare for treating insomnia is a useful read for anyone making that comparison at the point of prescribing.
And then there is the issue that medication never resolves: the mechanisms maintaining the insomnia remain entirely intact. The hyperarousal, the conditioned wakefulness, the dysfunctional sleep beliefs — medication suppresses symptoms while these drivers continue running in the background. When the prescription ends, rebound insomnia is common, the patient is back in your office, and the path of least resistance is a refill. This is how patients end up on sleep medication for years despite the original intention to use it briefly.
Xanax for insomnia and why it's not a long-term solution makes the same point in the benzodiazepine context: dependency risk compounds over months, discontinuation provokes rebound worsening, and the underlying insomnia pattern has never been touched.
The recommendation is not ambiguous. The American College of Physicians 2016 clinical practice guideline states that all adult patients should receive Cognitive Behavioral Therapy for Insomnia as the initial treatment for chronic insomnia disorder, with pharmacotherapy considered only when CBT-I is unsuccessful or unavailable. The American Academy of Sleep Medicine, the European Sleep Research Society, and the NIH Consensus Conference on Insomnia have each reached the same conclusion through independent review of the same evidence base.
The reason medication continues to dominate in practice is not clinical — it's logistical. In-person CBT-I therapists are scarce, waitlists are long, insurance coverage has historically been unreliable, and the alternative to writing a script has felt like giving the patient nothing. That access problem has now been solved in ways it hadn't been even a few years ago. But before getting to delivery, it's worth being precise about what CBT-I is and why it works so reliably.
CBT-I is a structured multicomponent intervention. "Sleep hygiene education" is not CBT-I. A relaxation app is not CBT-I. Understanding the distinction matters for clinician credibility when recommending it.
The 3 P's model of insomnia — predisposing, precipitating, and perpetuating factors — is the conceptual foundation. Most patients come to you well past the precipitating event (a medical illness, a stressor, a period of shift work) and deeply embedded in the perpetuating factors: time in bed extended beyond actual sleep capacity, conditioned arousal to the sleep environment, hypervigilance about sleep, catastrophizing about daytime consequences. Medication addresses none of this. CBT-I addresses all of it.
Sleep restriction therapy is the most active component. By temporarily compressing time in bed to match actual sleep time, it builds homeostatic sleep pressure and consolidates fragmented, inefficient sleep into a more continuous block. Patients resist this initially — it sounds counterintuitive to spend less time in bed when you're already not sleeping enough. Sleep compression as a technique for improving sleep quality explains the mechanism and why the short-term discomfort produces lasting structural change in sleep architecture.
Stimulus control dismantles the conditioned association between the bed and wakefulness. After months or years of lying awake in bed — clock-watching, doom-scrolling, anxious about why they keep waking up multiple times during the night — the bedroom itself has become a cue for arousal. Restricting bed use to sleep and sex, and getting up when unable to sleep, rebuilds the automatic association that healthy sleepers have and insomnia patients have lost.
Cognitive restructuring addresses the thought patterns that maintain hyperarousal at night: magnified estimates of sleep loss, catastrophic predictions about next-day functioning, identity-level beliefs about being a bad sleeper. For patients who describe a rush of anxiety when falling asleep or who experience what feels like a fight-or-flight response in the middle of the night, cognitive restructuring targets the neural pathway maintaining that arousal — not its surface symptoms.
The result is durable. Unlike medication, which produces symptomatic improvement only while taken, CBT-I changes the underlying pattern. Multiple follow-up studies at six and twelve months show that gains from CBT-I are maintained or continue improving after the active treatment period ends.
The most common sleep complaint in adults over 65 is not difficulty falling asleep — it's difficulty staying asleep: frequent nighttime waking, early-morning waking, and non-restorative sleep despite adequate time in bed. Understanding the causes of waking up at night and the role of light sleep in older adults both point to the same underlying mechanism: sleep architecture shifts with age toward lighter, more fragmented sleep, particularly in the second half of the night.
This is precisely the profile that CBT-I's sleep restriction and stimulus control components are most effective at treating. A landmark randomized trial in JAMA demonstrated CBT-I produced significantly greater improvements in sleep efficiency and total sleep time in older adults compared to controls, with effects sustained at follow-up. For patients worried about early-morning waking specifically, understanding the reasons for waking up too early and what the science says about 3AM wake-ups can help them understand what the intervention is targeting and why.
For postmenopausal women — a population where insomnia is dramatically underdiagnosed as a hormonal issue rather than a primary sleep disorder — the hidden link between menopause, hormones, and nighttime waking is particularly worth understanding before deciding on a treatment approach. Hormonal factors may be perpetuating the insomnia pattern, but CBT-I addresses the behavioral and cognitive layer that medication leaves untouched regardless of etiology.
And crucially for this population: no fall risk, no drug interactions, no anticholinergic burden, no dependency, no rebound on discontinuation. For a patient already managing multiple chronic conditions and medications, that absence of pharmacological risk is a meaningful clinical advantage in itself.
Patients will ask about supplements before and after any structured program. A brief evidence-based framework is useful to have.
Low-dose melatonin (0.5–1mg taken 60–90 minutes before bed) has reasonable evidence for circadian phase advancement in older adults whose sleep timing has shifted earlier. Melatonin dosage and what dose actually helps sleep and melatonin side effects and dosage considerations are both worth pointing patients to before they self-medicate. The common mistake is taking too much — a 10mg dose is not more effective than 0.5mg and carries risks worth understanding. Whether melatonin can make anxiety worse is also relevant for patients with comorbid anxiety driving their insomnia.
Magnesium glycinate has some evidence supporting reduced nighttime waking and improved subjective sleep quality. The best magnesium-rich foods to improve sleep naturally and GABA for sleep and whether it can calm the mind are useful patient-facing reads.
L-theanine versus melatonin and which one to take for sleep is a common patient question worth being able to answer directly: L-theanine may reduce pre-sleep anxiety without causing sedation, while melatonin is more useful for timing than for sleep maintenance. Neither replaces a behavioral program for chronic insomnia.
What doesn't belong in the recommendation: diphenhydramine (anticholinergic burden, cognitive risk in older adults), high-dose melatonin (limited additional benefit, increased side effect profile), and herbal combinations without standardized dosing.
Sleep Reset is a digital sleep medicine platform that delivers clinician-supervised CBT-I through a structured, adaptive program with dedicated coach support. This distinction matters: it is not a content library, not an automated chatbot, not a meditation app. The CBT-I-based program adapts in real time to each patient's sleep diary data, adjusting the sleep window and pacing the behavioral and cognitive components appropriately. Patients are supported throughout by trained sleep coaches — human interaction, not automated responses.
The clinical team is real. Sleep Reset's medical experts and staff include licensed sleep medicine physicians with formal academic backgrounds. The program is built on the same CBT-I evidence base summarized above, and patient reviews consistently reflect meaningful improvement in people who had been struggling with chronic insomnia and medication dependency for years.
For patients currently on sleep medication, Sleep Reset's clinical model is specifically designed to support concurrent deprescribing — a structured behavioral program running in parallel with a supervised taper significantly reduces the rebound insomnia and anxiety that make unassisted tapering so difficult. Breaking the cycle of fragmented sleep outlines the strategic approach the program takes.
Sleep Reset accepts major insurance plans and operates via telehealth, which solves the logistical barrier that has made CBT-I referrals impractical in most primary care settings. Which telehealth platforms offer insurance-covered sleep care including CBT-I and sleep apnea treatment provides a direct comparison for practices evaluating their referral options.
For patients who are not sure whether they qualify or where to start, Sleep Reset's looking-for-help page provides an accessible intake pathway, and the team is reachable directly at the contact page.
Most patients accept the evidence for CBT-I readily once it's framed clearly. The resistance usually comes from two places: unfamiliarity with what it actually involves, and fear that they'll be left without anything while they wait for a behavioral program to work.
On the first point: a plain-language explanation of CBT-I and what waking up rested actually requires are useful patient-facing resources that contextualize why the behavioral approach is different from generic sleep hygiene. For patients dealing with racing thoughts or nighttime anxiety as a driver of their waking, how to stop overthinking at night and why they can't sleep even when exhausted can help them understand what they're actually dealing with.
On the second point: behavioral and supplemental tools like low-dose melatonin, sound environments, sleep affirmations, and the 10-3-2-1-0 pre-sleep protocol give patients something to do immediately while they start a structured program — bridging the gap without adding a pharmacological risk.
For patients with sleep apnea as a possible comorbidity — particularly older women presenting with insomnia, fatigue, and mood symptoms rather than obvious snoring — the sleep apnea overview is a useful clinical starting point before layering CBT-I onto an undiagnosed breathing disorder.
The evidence-based alternative to sleep medication for older patients is CBT-I, delivered through a program with clinical structure, human support, and the ability to adapt to individual sleep patterns. It is the first-line recommendation of every major guideline body. It outperforms medication in long-term outcomes. It carries no fall risk, no drug interactions, no dependency risk, and no rebound on discontinuation.
The access barrier that historically prevented its use has been substantially reduced by digital delivery platforms with insurance coverage and telehealth access. The referral is now as practical as a prescription — and considerably more likely to produce lasting results.
Sleep Reset is where to start.
Sleep Reset is a clinician-backed digital sleep medicine platform offering CBT-I, home sleep testing, and insurance-covered telehealth care for patients with insomnia and sleep disorders. View Sleep Reset's medical team and clinical methodology.
Dr. Areti Vassilopoulos | Psychologist | Sleep Medicine Expert
Dr. Vassilopoulos is the Clinical Content Lead for Sleep Reset and Assistant Professor at Yale School of Medicine. She has co-authored peer-reviewed research articles, provides expert consultation to national nonprofit organizations, and chairs clinical committees in pediatric health psychology for the American Psychological Association. She lives in New England with her partner and takes full advantage of the beautiful hiking trails.
Fax: +1 (984) 888-8385
.jpg)
.jpeg)